drugset / Trial / NCT00035932

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

NCT00035932

Phase 3 Completed 571 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to learn how well atazanavir (ATV) works in combination with ritonavir (RTV) or saquinavir (SQV) with tenofovir (TDF) and a nucleoside to reduce the viral load of treatment experienced subjects with human immunodeficiency virus (HIV). There is a comparison arm with lopinavir (LPV)/RTV and TDF and a nucleoside.

Timeline

Start
2001-11
Primary completion
2003-07
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atazanavir Other / unclassified 300 mg Oral
Comparator Atazanavir Other / unclassified 400 mg Oral
Comparator Lopinavir Other / unclassified 400 mg Oral
Comparator Ritonavir Other / unclassified 100 mg Oral
Comparator Saquinavir Small molecule 1200 mg Oral
Comparator Tenofovir Small molecule 300 mg Oral